201 related articles for article (PubMed ID: 15549353)
1. Optimising MS disease-modifying therapies: antibodies in perspective.
Giovannoni G
J Neurol; 2004 Sep; 251 Suppl 5():v30-v35. PubMed ID: 15549353
[TBL] [Abstract][Full Text] [Related]
2. Neutralizing antibodies to interferon.
Noronha A
Neurology; 2007 Jun; 68(24 Suppl 4):S16-22. PubMed ID: 17562846
[TBL] [Abstract][Full Text] [Related]
3. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy.
Sorensen PS; Koch-Henriksen N; Ross C; Clemmesen KM; Bendtzen K;
Neurology; 2005 Jul; 65(1):33-9. PubMed ID: 15888603
[TBL] [Abstract][Full Text] [Related]
4. [The formation and significance of antibodies to interferon beta during immunomodulating treatment of multiple sclerosis].
Bartosik-Psujek H; Stelmasiak Z
Neurol Neurochir Pol; 2004; 38(1 Suppl 1):S53-6. PubMed ID: 15045868
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and tolerability of an investigational formulation of interferon-beta1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis.
Giovannoni G; Barbarash O; Casset-Semanaz F; Jaber A; King J; Metz L; Pardo G; Simsarian J; Sørensen PS; Stubinski B;
Clin Ther; 2007 Jun; 29(6):1128-45. PubMed ID: 17692727
[TBL] [Abstract][Full Text] [Related]
6. Is the treatment effect of IFN-beta restored after the disappearance of neutralizing antibodies?
Sorensen PS; Koch-Henriksen N; Flachs EM; Bendtzen K
Mult Scler; 2008 Jul; 14(6):837-42. PubMed ID: 18505772
[TBL] [Abstract][Full Text] [Related]
7. Are ex vivo neutralising antibodies against IFN-beta always detrimental to therapeutic efficacy in multiple sclerosis?
Sorensen PS; Koch-Henriksen N; Bendtzen K
Mult Scler; 2007 Jun; 13(5):616-21. PubMed ID: 17548440
[TBL] [Abstract][Full Text] [Related]
8. Incorporation of an interferon-β neutralizing antibody assay into routine clinical practice.
Farrell RA; Espasandin M; Lakdawala N; Creeke PI; Worthington V; Giovannoni G
Mult Scler; 2011 Nov; 17(11):1333-40. PubMed ID: 21685230
[TBL] [Abstract][Full Text] [Related]
9. Early detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development.
Hegen H; Millonig A; Bertolotto A; Comabella M; Giovanonni G; Guger M; Hoelzl M; Khalil M; Killestein J; Lindberg R; Malucchi S; Mehling M; Montalban X; Polman CH; Rudzki D; Schautzer F; Sellebjerg F; Sørensen PS; Deisenhammer F
Mult Scler; 2014 Apr; 20(5):577-87. PubMed ID: 24009164
[TBL] [Abstract][Full Text] [Related]
10. Study of binding and neutralising antibodies to interferon-beta in two groups of relapsing-remitting multiple sclerosis patients.
Fernández O; Mayorga C; Luque G; Guerrero M; Guerrero R; Leyva L; León A; Blanca M
J Neurol; 2001 May; 248(5):383-8. PubMed ID: 11437159
[TBL] [Abstract][Full Text] [Related]
11. Using measurements of neutralizing antibodies: the challenge of IFN-beta therapy.
Hesse D; Sørensen PS
Eur J Neurol; 2007 Aug; 14(8):850-9. PubMed ID: 17662004
[TBL] [Abstract][Full Text] [Related]
12. HLA alleles as biomarkers of high-titre neutralising antibodies to interferon-β therapy in multiple sclerosis.
Núñez C; Cénit MC; Alvarez-Lafuente R; Río J; Fernández-Arquero M; Arroyo R; Montalbán X; Fernández O; Oliver-Martos B; Leyva L; Comabella M; Urcelay E
J Med Genet; 2014 Jun; 51(6):395-400. PubMed ID: 24748646
[TBL] [Abstract][Full Text] [Related]
13. Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis.
Polman CH; Bertolotto A; Deisenhammer F; Giovannoni G; Hartung HP; Hemmer B; Killestein J; McFarland HF; Oger J; Pachner AR; Petkau J; Reder AT; Reingold SC; Schellekens H; Sørensen PS
Lancet Neurol; 2010 Jul; 9(7):740-50. PubMed ID: 20610349
[TBL] [Abstract][Full Text] [Related]
14. A sensitive radioimmunoprecipitation assay for assessing the clinical relevance of antibodies to IFN beta.
Lawrence N; Oger J; Aziz T; Palace J; Vincent A
J Neurol Neurosurg Psychiatry; 2003 Sep; 74(9):1236-9. PubMed ID: 12933925
[TBL] [Abstract][Full Text] [Related]
15. Biological activity of interferon betas in patients with multiple sclerosis is affected by treatment regimen and neutralising antibodies.
Bertolotto A; Sala A; Malucchi S; Marnetto F; Caldano M; Di Sapio A; Capobianco M; Gilli F
J Neurol Neurosurg Psychiatry; 2004 Sep; 75(9):1294-9. PubMed ID: 15314118
[TBL] [Abstract][Full Text] [Related]
16. Neutralising antibodies to interferon beta in multiple sclerosis : expert panel report.
Hartung HP; Polman C; Bertolotto A; Deisenhammer F; Giovannoni G; Havrdova E; Hemmer B; Hillert J; Kappos L; Kieseier B; Killestein J; Malcus C; Comabella M; Pachner A; Schellekens H; Sellebjerg F; Selmaj K; Sorensen PS
J Neurol; 2007 Jul; 254(7):827-37. PubMed ID: 17457510
[TBL] [Abstract][Full Text] [Related]
17. Correlation between anti-interferon-β binding and neutralizing antibodies in interferon-β-treated multiple sclerosis patients.
Jensen PE; Sellebjerg F; Søndergaard HB; Sørensen PS
Eur J Neurol; 2012 Oct; 19(10):1311-7. PubMed ID: 22564111
[TBL] [Abstract][Full Text] [Related]
18. Strategies to treat and prevent the development of neutralizing anti-interferon-beta antibodies.
Giovannoni G
Neurology; 2003 Nov; 61(9 Suppl 5):S13-7. PubMed ID: 14610104
[TBL] [Abstract][Full Text] [Related]
19. The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis.
Koch-Henriksen N; Sorensen PS; Bendtzen K; Flachs EM
Mult Scler; 2009 May; 15(5):601-5. PubMed ID: 19299439
[TBL] [Abstract][Full Text] [Related]
20. Persistency of neutralizing antibodies depends on titer and interferon-beta preparation.
Hegen H; Schleiser M; Gneiss C; Di Pauli F; Ehling R; Kuenz B; Lutterotti A; Berger T; Deisenhammer F
Mult Scler; 2012 May; 18(5):610-5. PubMed ID: 22013146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
